Emerson (EMR) Q3 2025 earnings review
Discrete Recovery Powers Strong Q4 Outlook and Raised Guidance
Emerson delivered a solid Q3, meeting expectations with 3% underlying sales growth and a 6% increase in Adjusted EPS to $1.52. The core story, however, is the accelerating momentum heading into the year-end. A sharp, confirmed recovery in discrete markets, highlighted by a 16% surge in Test & Measurement orders, underpins a robust Q4 forecast for 5-6% underlying sales growth. This confidence allowed management to raise its full-year Adjusted EPS guidance to ~$6.00 and its free cash flow outlook to ~$3.2 billion, signaling that the long-awaited rebound is finally materializing.
🐂 Bull Case
The long-awaited recovery in discrete markets has arrived. Test & Measurement orders surged 16% and are expected to approach 20% in Q4, providing a powerful growth engine heading into FY26.
Management's confidence is reflected in raised full-year guidance for Adjusted EPS (to ~$6.00) and Free Cash Flow (to ~$3.2B), indicating a strong finish to the year and positive operational leverage.
The company generated $970 million in free cash flow, demonstrating excellent cash conversion on earnings and providing flexibility for capital allocation.
🐻 Bear Case
The company's largest segment, Intelligent Devices, saw its adjusted margin contract by 110 basis points to 24.4% due to tariffs and unexpected currency headwinds, weighing on overall profitability.
Europe remains a significant weak spot, with underlying sales declining 7% year-over-year. A recovery in the region is needed for the company to achieve its full growth potential.
⚖️ Verdict: 🟢
Bullish. While the Q3 results were in-line, the forward-looking indicators are compelling. The sharp acceleration in orders, particularly in the bellwether Test & Measurement segment, confirms the recovery narrative. The subsequent increase in full-year EPS and cash flow guidance outweighs the margin pressure in a single segment, suggesting the positive momentum is broad and sustainable.
Key Themes
Test & Measurement Recovery Ignites Discrete Growth
The recovery in discrete end markets is no longer a forecast; it's a reality. Underlying orders for the Test & Measurement business surged 16% in Q3, a sharp inflection from previous declines. Management noted broad-based strength and expects this momentum to build, with order growth approaching 20% in Q4. This validates the company's strategy and provides a strong tailwind for sales growth acceleration into FY26.
Margin Compression in Intelligent Devices
Contrary to the strong overall profit story, the Intelligent Devices segment, which accounts for nearly 70% of sales, experienced a notable margin decline. Adjusted EBITA margin fell to 24.4% from 25.5% a year ago. Management attributed the drop to both expected tariff impacts and an 'unexpected' headwind from foreign exchange. This highlights a vulnerability in the company's largest business, even as other segments perform well.
Process & Hybrid Markets Remain Resilient
While the discrete recovery took center stage, Emerson's core Process and Hybrid businesses continued their steady performance with mid-single-digit order growth. Demand is fueled by long-cycle investments in LNG, Life Sciences, and Power. The Power market was a particular bright spot, with orders for the Ovation control system platform up an impressive 40% in the quarter, driven by global demand for increased electricity generation.
Innovation in Industrial AI
Emerson showcased significant progress in its industrial software portfolio by launching its first Generative AI-powered tools. The 'Ovation AI-enabled Virtual Adviser' integrates with its flagship power generation control system, while the 'Nigel AI adviser' is being added to its LabVIEW software for the test and measurement market. These innovations demonstrate a clear strategy to lead in software-defined automation and create new, high-margin revenue streams.
Tariff Environment Improves
The tariff situation proved less severe than anticipated. The estimated gross impact for FY25 has been reduced from $245 million to $130 million. This improvement allowed Emerson to ease some of its price surcharges for customers in Q3. While still a headwind, the reduced exposure de-risks the margin outlook and led to a slight reduction in the full-year sales growth forecast, as less pricing is now required.
Europe Remains a Drag on Growth
Geographically, Europe was the main source of weakness, with underlying sales declining 7% year-over-year. This contrasts with 7% growth in the Americas and 2% in Asia, Middle East & Africa. While management expects an acceleration in Europe, its persistent underperformance is a headwind to achieving higher corporate growth rates.
Other KPIs
The company demonstrated robust cash generation, with Q3 FCF up 27% YoY. This performance, driven by higher earnings and working capital improvements, led management to increase its full-year FCF guidance to approximately $3.2 billion, signaling strong operational health.
This segment continues to be a profit engine, with margins expanding over 230 basis points from 30.3% last year. The high profitability, driven by AspenTech synergies and a favorable software mix, provides a crucial offset to margin pressures elsewhere in the portfolio.
Guidance
Accelerating. This guidance implies a significant step-up from Q3's 3% growth rate. The acceleration is primarily driven by the strong order book and anticipated sales conversion in the recovering Test & Measurement business.
Stable/Improving. The guidance was raised from a previous midpoint of $5.98. This reflects the Q3 beat and confidence in a strong operational finish to the year, with year-over-year growth expected to be approximately 9%.
Stable. This represents a slight trim from the previous ~4.0% guidance. Management clarified this is not due to weaker demand but reflects the decision to ease pricing surcharges as the expected tariff impact has been reduced.
Key Questions
Intelligent Devices Margin Outlook
You attributed the 110 bps margin decline in Intelligent Devices to tariffs and unexpected FX. Can you quantify the FX impact and provide confidence that the pricing actions in Q4 will be sufficient to restore margin expansion in that segment?
Drivers of Sales Guidance Trim
You trimmed the full-year underlying sales guide from ~4% to ~3.5% while citing an accelerating recovery. Was this reduction entirely due to easing the tariff surcharges, or are there any pockets of demand, aside from Europe, that are tracking slightly below prior expectations?
Test & Measurement Profitability
With Test & Measurement orders inflecting sharply positive but sales still negative this quarter, what is the expected margin trajectory for this business as volume returns in Q4 and into FY26? Will operating leverage be significantly above the corporate average?